Karyopharm Therapeutics Inc. (KPTI) has a potential near-term catalyst this month as it awaits developments from a clinical trial evaluating an expanded indication for its lead drug, Selinexor.
Selinexor, a first-in-class Selective Inhibitor of Nuclear Export (SINE) XPO1 antagonist, is already approved for the treatment of adult patients with multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma, under the brand name Xpovio.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.